Ballicules.com

Crinecerfont

CRENESSITY

What it isCRF1 antagonist reducing pituitary ACTH drive; classic congenital adrenal hyperplasia.

Why this oneIt lowers adrenal androgen drive so glucocorticoids can move toward replacement rather than chronic supraphysiologic suppression.

What limits itReducing glucocorticoids too quickly can trigger adrenal insufficiency; CYP3A4 interactions require review.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Congenital adrenal hyperplasia (adjunct to glucocorticoid)Adults100 mg BID with a meal (AM & PM)100 mg BID100 mg BID
Congenital adrenal hyperplasia (adjunct to glucocorticoid)Peds ≥4 y, weight-based10–<20 kg: 25 mg BID; 20–<55 kg: 50 mg BID; ≥55 kg: 100 mg BID25–100 mg BID by weight100 mg BID

Renal Undefined

Hepatic Undefined

With strong CYP3A4 inducers, increase dose: adults 200 mg BID; pediatrics per weight table

Instructions

Cautions

Adverse reactions

Pregnancy Data insufficient; low incidence of craniofacial malformations in rabbits at 2× exposure

Lactation No human milk data; present in animal milk; monitor infant for adrenal insufficiency

NO BOXED WARNINGS

Principal riskAdrenal insufficiency if glucocorticoid is cut too fast

Cost, est. cash$7,000–$12,000/month

Generic entry2038 est.

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Crinecerfont ballicule

Crinecerfont ballicule: receptor binding, kinetics and half-life diagram

Open Crinecerfont in the interactive console ↗